FDA approves first biosimilar for the treatment of cancer

September 14, 2017 – The U.S. Food and Drug Administration today approved bevacizumab-awwb as a biosimilar to bevacizumab for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower healthcare costs … (leggi tutto)